A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Translational Vaccine Research

Division of Translational Vaccine Research
The LVR was formed by Dr. Diamond in 2000 to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope (COH) and other cancer centers worldwide. In 2008, Dr. Diamond formed the TVR to expand the work started in the LVR towards additional tumor types and to accelerate clinical development of promising vaccine strategies. The foundation of the research priorities of the program grew out of the extensive collaboration with the Hematopoietic Stem Cell Transplant Program at COH, and the need for an effective therapeutic strategy for infections post-transplant (Tx). The infection that has historically played a major role in reducing Tx success rate is the herpes virus called cytomegalovirus (CMV). In 1993 an immunologic approach was developed for controlling this virus, and this work has continued. The TVR has a two pronged attack on virus infection using two different but allied approaches for therapy. The first approach relies on a non-living synthetic portion of the virus called a peptide that has cleared its safety hurdle after a successful clinical trial in healthy volunteers. The peptide is now undergoing preliminary efficacy testing in stem cell transplant recipients at COH. The goal of this trial is to measure if it is immunologically recognized. In cooperation with physicians at the University of Minnesota, we are expanding the evaluation to cover all types of stem cell transplant including cord blood. The goal is to discover if it is protective against CMV infection and substitutes for toxic anti-viral drugs that hamper recovery. The 2nd approach is nearing submission to the FDA for review and permission to conduct a 1st in humans safety trial. While the peptide applies to about 40% of transplant recipients, the newer approach would be universal in coverage. It is designed to protect both stem cell and solid organ transplant recipients. We anticipate the 1st safety trial to begin in late 2013.

Based on work initiated 2 decades ago with former COH surgical oncologist and clinical researcher, Dr. Joshua D.I. Ellenhorn, a Phase 1 safety trial of a cancer vaccine was started in early 2012. Gastro-intestinal patients with inoperable disease are receiving the vaccine, and TVR personnel are monitoring its immunologic recognition, while Dr. Vincent Chung, a COH medical oncologist is assessing clinical responses based on CT-scans. Using a different vector system based on an attenuated Salmonella strain, TVR investigators have developed a therapeutic strategy that applies to a large panel of solid tumors and melanoma. The strategy depends on using RNAi to deplete immunosuppressive molecules to allow anti-tumor immunity to flourish. We are also trying to adopt this therapy to brain cancer, where immunosuppression is strong and standard approaches have largely failed.

Continuing the theme of brain injury, we are pursuing a vaccine strategy to prevent birth defects that strongly impact lifelong cognitive abilities. Interestingly, the culprit is still CMV, but in this case it infects women of child-bearing years who were never previously exposed, and causes harm to over 4000 neonates annually in the USA. We are in the process of developing a more effective vaccine than one already investigated and found only to be 50% effective at controlling CMV infection in neonates.

We welcome inquiries about our ongoing programs, TVR investigators, and outside collaborators who are leading the research effort.

Translational Vaccine Research Projects

Evaluation of safety and correlative immunogenicity studies of CMVPepVax co-injected with PF03512676 adjuvant in recipients of allogeneic stem cell transplant
CMVPepVax to protect stem cell transplant recipients from Cytomegalovirus infection-University of Minnesota collaborative study
Control of CMV infection in allogeneic stem cell transplant recipients using attenuated MVA-based CMV subunit vaccine
A Phase I study of a p53-MVA vaccine for advanced colon, gastric and pancreatic cancer
HCMV vaccine Produced from BAC-MVA that blocks epithelial and fibroblast entry
Evaluation of protective CMV vaccines in rhesus macaques
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
WT1 as a biomarker topredict relapse in patients with acute leukemia and MDS
Project 9
Optimizing shRNA approaches for control of Lymphoma using Salmonella delivery systems

TVR Lab Members

Research Group
Associate Research Professor
Edwin Manuel, PhD
Staff Scientist
Post-Doctoral Fellow
Post-Doctoral Fellow
Post-Doctoral Fellow
Post-Doctoral Fellow
Post-Doctoral Fellow
Post-Doctoral Fellow
Joy Martinez
Senior Research Associate
John Campo
Research Associate
Sarah August
Cal-Poly Masters Candidate
Melanie Lampa
Laboratory Manager
Administrative Team
Peter Kwon
Administrative Analyst
Donna Packer
Administrative Support

Grant Support

07/01/13 – 06/30/15
R21 CA0174306-01A1      
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). (Impact Score=20, 3%)
Role: Principal Investigator
05/15/13 – 04/30/17
R01 AI103960-01A1 (Diamond & Barry)   
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry
The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)

05/01/12 - 12/31/17
5R01 CA077544-12 (Diamond)      
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine
The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator

02/15/10 - 01/31/15
5R01 AI063356-10   (Barry & Diamond)                  
Evaluation of Protective CMV Vaccines in Rhesus Macaques
The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator

04/01/12 – 05/31/14
Nesvig Foundation (Diamond)         
Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems
The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator

Current Job Openings

None at this time.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Welcome to City of Hope
City of Hope is a new model of cancer center, focused on rapidly transforming scientific discoveries into better treatments and better prevention strategies for cancer, diabetes, HIV/AIDS and other life-threatening diseases.

Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
  • For breast cancer survivors, a common worry is a recurrence of their cancer. Currently, these patients are screened with regular mammograms, but there’s no way to tell who is more likely to have a recurrence and who is fully cleared of her cancer. A new blood test – reported in Cancer Research, a journal of the...
  • Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process. Now City of Hope researchers may have identified a substa...
  • Deodorant, plastic bottles, grilled foods, artificial sweeteners, soy products … Do any of these products really cause cancer? With so many cancer myths and urban legends out there, why not ask the experts? They can debunk cancer myths while sharing cancer facts that matter, such as risk factors, preventi...
  • Cancer risk varies by ethnicity, as does the risk of cancer-related death. But the size of those differences can be surprising, highlighting the health disparities that exist among various ethnic groups in the United States. Both cancer incidence and death rates for men are highest among African-Americans, acco...
  • George Winston, known worldwide for his impressionistic, genre-defying music, considers music to be his first language, and admits he often stumbles over words – especially when he attempts languages other than English. There’s one German phrase he’s determined to perfect, however: danke schön. Winston thinks h...
  • Few decisions are more important than those involving health care, and few decisions can have such lasting impact, not only on oneself but on relatives and loved ones. Those choices, especially, should be made in advance – carefully, deliberately, free of pain and stress, and with much weighing of values and pr...
  • Using a card game to make decisions about health care, especially as those decisions relate to the end of life, would seem to be a poor idea. It isn’t. The GoWish Game makes those overwhelming, but all-important decisions not just easy, but natural. On each card of the 36-card deck is listed what seriously ill,...
  • Young adults and adolescents with cancer face unique challenges both during their treatment and afterward. Not only are therapies for children and older adults not always appropriate for them, they also must come to terms with the disease and treatment’s impact on their relationships, finances, school or ...
  • Breast cancer is the most common cancer, other than skin cancer, among women in the United States. It’s also the second-leading cause of cancer death, behind lung cancer. In the past several years, various task force recommendations and studies have questioned the benefits of broad screening guidelines fo...
  • Paternal age and the health effects it has on potential offspring have been the focus of many studies, but few have examined the effect parental age has on the risk of adult-onset hormone-related cancers (breast cancer, ovarian cancer and endometrial cancer). A team of City of Hope researchers, lead by Yani Lu,...
  • Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal h...
  • Myeloproliferative neoplasms can’t be narrowed down to a single cancer, but they can be described by a defining characteristic: too many blood cells. The diseases bring with them a host of frustrating, potentially life-altering symptoms, and management of the diseases and their symptoms is crucial. An upcoming ...
  • More than 18,000 researchers, clinicians, advocates and other professionals will convene at the 105th American Association for Cancer Research (AACR) annual meeting taking place in San Diego from April 5 to 9. With more than 6,000 findings being presented over this five-day period, the amount of information can...
  • Cancer of the prostate is the No. 2 cancer killer of men, behind lung cancer, accounting for more than 29,000 deaths annually in this country. But because prostate cancer advances slowly, good prostate health and early detection can make all the difference. Many prostate cancer tumors don’t require immedi...
  • Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer’s ability to resist treatment, renderi...